June 2 (Reuters) - AstraZeneca PLC :
* FDA advisory committee reviews medimmune's motavizumab
* Medimmune - US FDA voted 14 to 3 to recommend that motavizumab should not be
licensed for marketing
* Medimmune - committee's recommendation will be considered by FDA reviewers in
their evaluation of bla for motavizumab
* Refile-medimmune-usfda committee voted 14 to 3 to recommend motavizumab
should not be licensed for marketing (adds dropped word)
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* FDA advisory committee reviews medimmune's motavizumab
* Medimmune - US FDA voted 14 to 3 to recommend that motavizumab should not be
licensed for marketing
* Medimmune - committee's recommendation will be considered by FDA reviewers in
their evaluation of bla for motavizumab
* Refile-medimmune-usfda committee voted 14 to 3 to recommend motavizumab
should not be licensed for marketing (adds dropped word)
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.